Need professional-grade analysis? Visit stockanalysis.com
$1.07B
N/A
117
N/A
DBV Technologies S.A. (DBV) trades on Euronext Paris in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR3.62, up 2.55% from the previous close.
Over the past year, DBV has traded between a low of EUR1.38 and a high of EUR4.26. The stock has gained 156.3% over this period. It is currently 15.0% below its 52-week high.
DBV Technologies S.A. has a market capitalization of $1.07B.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Side-by-side comparison against top Healthcare peers.